|
Career:
| 1978.3- 1985.2: |
MD. Seoul National University College of Medicine |
| 1994.3- 1996.2: |
MS, Seoul National University, (Biochemistry) |
| 1996.9- 2001.4: |
Ph.D, Harvard School of Public Health, (Environmental Molecular
Epidemiology) |
| 1985.3- 1988 2: |
Intern and Resident, Seoul National University Hospital, (Family
Medicine) |
| 1995.9 - 1996.8 : |
Research Fellow, Harvard School of Public Health, (Cancer Cell
Biology) |
| 2001.3- 2002.4: |
Research Fellow, Harvard Medical School, Dana Farber Cancer
Institute, (Adult Oncology) |
Research:
Early detection of human cancer
A major focus of our laboratory is upon the study of DNA methylation as a biomarker
for early detection of major human cancers, including cancers of lung, stomach, colon,
esophagus, liver, breast, brain etc. Despite many progress in treatment and detection
methods, the prognosis of most human cancers is still very poor. The poor prognosis
of cancer patients results from largely micrometastasis, which occurs in more than a half
of patients at the time of diagnosis. Therefore, it is clearly imperative to develop efficient
diagnostic methods that can detect the cancer at the earliest stages of human cancers in
which curative surgical resection is feasible. One promising approach is to identify
cancer-specific molecular biomarkers, especially those that are associated with the initiation
and progression of human cancer at the earliest stage. The de novo methylation of CpG islands
within the promoters of tumor suppressor genes is one of frequent mechanisms of gene inactivation
in human neoplastic cells and is one of the most frequently acquired epigenetic changes occurring
in the carcinogenesis of human cancer. Thus, aberrant methylation status of genes important in the
pathogenesis of human cancer can make a good biomarker for the early detection and follow-up
of major human cancers.
Mechanism of increased DNA methyltransferase in cancer
Another interest of our laboratory is to investigate the possible mechanism of DNA methylation
and to discover new demethylating agents for the treatment of cancer patients. DNA
methyltransferases (DNMTs) are known to play an important role in the development of human
cancer, but the underlying mechanism responsible for the altered expression of DNMT remains
to be elucidated. Emphasis has been placed on DNMT activity and on retinoblastoma protein,
pRb. This work is being undertaken in an effort to understand more fully how DNMT activity
is regulated by pRb. We hypothesize that pRb might regulate DNMT activity through a Ras signaling
pathway. We also work on the development of new drugs such as DNMT inhibitor and histone deacetylase inhibitor
for the treatment of cancer.
Publications:
- Kim H, Kwon, YM, Kim JS, Han J, Shim YM, Park J, and Kim DH. Elevated mRNA levels of DNA methyltransferase 1 as an independent prognostic factor in primary non-small cell lung cancer. Cancer, 107: 1042-1049, 2006.
- Kim JS, Kim JW, Han J, Shim YM, Park J, Kim DH. Cohypermethylation of p16 and FHIT Promoters as a Prognostic Factor of Recurrence in Surgically Resected Stage 1 Non-Small Cell Lung cancer. Cancer Research, 66: 4049-4054, 2006.
- Kim JJ, Chung SW, Kim JH, Kim JW, Oh JS, Kim S, Song SY, Park J, Kim DH. Promoter methylation of helicase-like transcription factor is associated with the early stages of gastric cancer with family history. Annals of Oncology, 17(4): 657-662, 2006.
- Kim JS, Han J, Shim YM, Park J, and Kim DH. Aberrant methylation of H-cadherin (CDH13) promoter is associated with tumor progression in primary non-small cell lung cancer. Cancer, 104: 1825-1833, 2005.
- Marsit CJ, Hasegawa MH, Hirao T, Kim DH, Aldape K, Hinds PW, Wiencke JK, Nelson HH,
and Kelsey KT. Loss of heterozygosity of chromosome 3p21 is associated with mutant TP53 and
better patient survival in non-small cell lung cancer. Cancer Research, 64: 8702-8707, 2004.
- Kim JS, Kim HJ, Shim YM, Han JH, Park JB, and Kim DH. Aberrant methylation of the FHIT
gene in chronic smokers with early stage squamous cell carcinoma of the lung. Carcinogenesis,
25: 2165-2171, 2004.
- Kim JS, Lee HB, Kim HJ, Shim YM, Han JH, Park JB, and Kim DH. Promoter methylation of
retinoic acid receptor b2 and the development of second primary lung cancers in non-small cell lung
cancer. J. Clin. Oncol, 22: 3443-3450, 2004.
- Kim HJ, Kwon YM, Kim JS, Lee HB, Park JH, Han JH, Park JB, and Kim DH. Tumor-specific
methylation in bronchial lavage for early detection on non-small cell lung cancer. J. Clin. Oncol, 22: 2363-2370, 2004.
- Kim DH, Kim JS, Ji YI, Shim YM, Kim HJ, Han JH, and Park JB. Hypermethylation of RASSF1A
promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell
lung cancer. Cancer Res, 63: 3743-3746, 2003.
- Kim DH, Kim JS, Park JH, Lee SK, Ji Yi, Kwon YM, Shim YM, Han JH, and Park JB. Relationship
of Ras association domain family 1 methylation and K-ras mutation in primary non-small cell lung cancer.
Cancer Res, 63, 6206-6211, 2003.
- Kim DH, Nelson HH, Wiencke JK, Zheng S, Christiani DC, Wain JC,?? Mark EJ, and Kelsey KT.
p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small
cell lung cancer. Cancer Res, 61(8):3419-24, 2001.
- Kim DH, Nelson HH, Wiencke JK, Christiani DC, Wain JC, Mark EJ, and Kelsey KT. Promoter
methylation of DAP-kinase: association with advanced stage in non-small cell lung cancer.
Oncogene, 20(14):1765-70, 2001.
|
